ClinicalTrials.gg
CompletedNCT00141128Updated Jun 1, 2011

Evaluation Of A Novel Methodology In The Assessment Of Urethral Function Using SS-RBX.

A Phase 2 interventional study of SS-RBX in Urinary Incontinence, Stress, sponsored by Pfizer. Completed at 1 site in Denmark. Open to female participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2011-06-01.

Sponsored by Pfizer · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
18
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies in Urinary Incontinence, Stress with a site in Denmark — 1 open to participants now, 2 under way, none of them phase 3. Urinary Incontinence, Stress · Denmark.

Enrollment
8th of 12
18 · median 23
Started
2005
the only one that year
Phase 2
2 of 15
none open now
Registered
1st of 15
by date
Lead sponsor
2 of 15
Pfizer

Among the 15 studies in Urinary Incontinence, Stress with a site in Denmark, this one is the 8th largest by enrollment of the 12 interventional ones that give a count, is the only one that started in 2005, is one of 2 in phase 2, and was the 1st registered.

Urinary Incontinence, Stress

653 studies on the registry are indexed under Urinary Incontinence, Stress; 122 are open to participants now.

Browse Urinary Incontinence, Stress studies →

Open to participants now

1 of the 15 studies in Urinary Incontinence, Stress with a site in Denmark is open now. Recruiting first, the newest first:

A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →

Who these studies take

Of the 75 Urinary Incontinence, Stress studies recruiting now, 42 (56%) set no upper age limit and 18 (24%) stop at 75 or younger; 2 take children under 18; 16 take healthy volunteers.

This study: 18 Years to 65 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Urinary Incontinence, Stress with a site in Denmark, or all of them as a file.
02

Study summary

SS-RBX will be used to evaluate pharmacodynamic changes in urethral function using a novel methodology

03

Conditions studied

  • Urinary Incontinence, Stress
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female
  • Stress urinary incontinence

Exclusion criteria

Exclusion Criteria:

  • Bladder outflow obstruction
  • Neurological disease
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double
Enrollment
18 participants (actual)

Interventions

06

What researchers measure

Primary outcomes

  1. To assess the utility of urethral reflectometry in the detection of pharmacologically induced pressure changes in the female urethra.

Secondary outcomes

  1. To assess the effect of [S,S]-Reboxetine on urethral function in women with SUI.

07

Study locations

1 site
  • Pfizer Investigational Site
    Glostrup, 2600, Denmark
08

References and documents

Publications

  • Klarskov N, Scholfield D, Soma K, Darekar A, Mills I, Lose G. Measurement of urethral closure function in women with stress urinary incontinence. J Urol. 2009 Jun;181(6):2628-33; discussion 2633. doi: 10.1016/j.juro.2009.01.114. Epub 2009 Apr 16. PubMed 19375093 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2005 and a completion of Jun 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 29, 2005
First posted
Sep 1, 2005
Start
Dec 2005
CompletionActual
Jun 2006
Last update
Jun 1, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 1, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00141128
Lead sponsor
Pfizer
First posted
Sep 1, 2005
Start date
Dec 2005
Completion
Jun 2006
Last update
Jun 1, 2011

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Esreboxetine

Start the discussion